3 “Under-Loved” Biotech Stocks With More Upside Potential Than Downside Risk

With COVID-19 vaccine stocks Pfizer and Moderna receiving so much attention, the author of today’s article notes that “This leaves a lot of biotech stocks lacking the attention they deserve. While this is bad news for current holders of these stocks, it is an opportunity for new ones.” With this in mind, he proceeds to highlight three “under-loved” biotech stocks with more upside potential than downside risk to consider for profits in 2021. For these three stocks, CLICK HERE.

Emerging Coronavirus Stocks: Potential Multi-Baggers

When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take a look at four such emerging coronavirus stocks – and why he believes that “investing $3,000 in any combination of them is a good idea.” CLICK HERE.